217 related articles for article (PubMed ID: 24273222)
1. A nationwide survey of hypertrophic pachymeningitis in Japan.
Yonekawa T; Murai H; Utsuki S; Matsushita T; Masaki K; Isobe N; Yamasaki R; Yoshida M; Kusunoki S; Sakata K; Fujii K; Kira J
J Neurol Neurosurg Psychiatry; 2014 Jul; 85(7):732-9. PubMed ID: 24273222
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic Pachymeningitis in Chinese Patients: Presentation, Radiological Findings, and Clinical Course.
Bi Z; Shang K; Cao J; Su Z; Bu B; Xu S; Liu C
Biomed Res Int; 2020; 2020():2926419. PubMed ID: 32879880
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of hypertrophic pachymeningitis in a center survey.
Cação G; Calejo M; Alves JE; Medeiros PB; Vila-Cha N; Mendonça T; Taipa R; Silva AM; Damásio J
Neurol Sci; 2019 Mar; 40(3):543-551. PubMed ID: 30588552
[TBL] [Abstract][Full Text] [Related]
4. Hypertrophic Pachymeningitis in a Southern Chinese Population: A Retrospective Study.
Xiao X; Fu D; Feng L
Front Neurol; 2020; 11():565088. PubMed ID: 33281701
[No Abstract] [Full Text] [Related]
5. Idiopathic hypertrophic pachymeningitis: an autoimmune IgG4-related disease.
De Virgilio A; de Vincentiis M; Inghilleri M; Fabrini G; Conte M; Gallo A; Rizzo MI; Greco A
Immunol Res; 2017 Feb; 65(1):386-394. PubMed ID: 27592235
[TBL] [Abstract][Full Text] [Related]
6. Distinct features of ANCA-associated hypertrophic pachymeningitis compared to other etiologies: findings from a study of 74 patients.
Martín-Nares E; Romero-Sánchez G; Cortez-Domínguez EU; Cano-Cruz LG; Hinojosa-Azaola A
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38759113
[TBL] [Abstract][Full Text] [Related]
7. IgG4-related hypertrophic pachymeningitis with ANCA-positivity: A case series report and literature review.
Xia C; Li P
Front Neurol; 2022; 13():986694. PubMed ID: 36188377
[TBL] [Abstract][Full Text] [Related]
8. Hypertrophic pachymeningitis.
Hahn LD; Fulbright R; Baehring JM
J Neurol Sci; 2016 Aug; 367():278-83. PubMed ID: 27423604
[TBL] [Abstract][Full Text] [Related]
9. [Hypertrophic pachymeningitis secondary to IgG4-related disease: case report and review of the literature].
Rodríguez-Castro E; Fernández-Lebrero A; López-Dequidt IA; Rodríguez-Osorio X; López-González FJ; Suárez-Peñaranda JM; Arias M
Rev Neurol; 2015 Oct; 61(7):308-12. PubMed ID: 26411275
[TBL] [Abstract][Full Text] [Related]
10. Imaging characteristics of hypertrophic pachymeningitis due to ANCA-associated vasculitis.
Takagi T; Okada M; Nakamura M; Hanari T; Nakata T; Teraoka M; Hato N
Auris Nasus Larynx; 2022 Oct; 49(5):875-879. PubMed ID: 35074241
[TBL] [Abstract][Full Text] [Related]
11. [Is hypertrophic pachymeningitis a dural lesion of IgG4-related systemic disease?].
Riku S; Hashizume Y; Yoshida M; Riku Y
Rinsho Shinkeigaku; 2009 Sep; 49(9):594-6. PubMed ID: 19928692
[TBL] [Abstract][Full Text] [Related]
12. [IgG4- and MPO-ANCA-associated hypertrophic pachymeningitis].
Aragonès JM; Arias-Rivero M; García-Barrionuevo JM; Lucchetti G
Rev Neurol; 2015 Nov; 61(10):454-7. PubMed ID: 26553176
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituximab.
Popkirov S; Kowalski T; Schlegel U; Skodda S
J Clin Neurosci; 2015 Jun; 22(6):1038-40. PubMed ID: 25861887
[TBL] [Abstract][Full Text] [Related]
14. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody.
Yokoseki A; Saji E; Arakawa M; Kosaka T; Hokari M; Toyoshima Y; Okamoto K; Takeda S; Sanpei K; Kikuchi H; Hirohata S; Akazawa K; Kakita A; Takahashi H; Nishizawa M; Kawachi I
Brain; 2014 Feb; 137(Pt 2):520-36. PubMed ID: 24271323
[TBL] [Abstract][Full Text] [Related]
15. Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers.
Saeki T; Fujita N; Kourakata H; Yamazaki H; Miyamura S
Clin Rheumatol; 2004 Feb; 23(1):76-80. PubMed ID: 14749992
[TBL] [Abstract][Full Text] [Related]
16. IgG4-related hypertrophic pachymeningitis of the spine with MPO-ANCA seropositivity.
Maher M; Zanazzi G; Faust P; Nickerson K; T Wong T
Clin Imaging; 2017; 46():108-112. PubMed ID: 28768224
[TBL] [Abstract][Full Text] [Related]
17. IgG4-related disease and hypertrophic pachymeningitis.
Wallace ZS; Carruthers MN; Khosroshahi A; Carruthers R; Shinagare S; Stemmer-Rachamimov A; Deshpande V; Stone JH
Medicine (Baltimore); 2013 Jul; 92(4):206-216. PubMed ID: 23793110
[TBL] [Abstract][Full Text] [Related]
18. [Hypertrophic cranial and spinal pachymeningitis. A description of four new cases and a review of the literature].
Jimenez-Caballero PE; Diamantopoulos-Fernandez J; Camacho-Castaneda I
Rev Neurol; 2006 Oct 16-31; 43(8):470-5. PubMed ID: 17033980
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic hypertrophic cranial pachymeningitis.
Sylaja PN; Cherian PJ; Das CK; Radhakrishnan VV; Radhakrishnan K
Neurol India; 2002 Mar; 50(1):53-9. PubMed ID: 11960152
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
Choi HA; Lee MJ; Chung CS
J Neurol; 2017 Apr; 264(4):724-732. PubMed ID: 28220286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
